These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23543601)

  • 1. Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation.
    Kelley M; Ahene AB; Gorovits B; Kamerud J; King LE; McIntosh T; Yang J
    AAPS J; 2013 Jul; 15(3):646-58. PubMed ID: 23543601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing Antibody: Biotherapeutic Modality-Based Review.
    Gorovits B; Clements-Egan A; Birchler M; Liang M; Myler H; Peng K; Purushothama S; Rajadhyaksha M; Salazar-Fontana L; Sung C; Xue L
    AAPS J; 2016 Mar; 18(2):311-20. PubMed ID: 26821802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitigation of Pre-existing Antibodies to a Biotherapeutic in Non-clinical Species When Establishing Anti-drug Antibody Assay Cutpoint.
    Kumar SC; DelCarpini JA; Qu Q; Kane M; Gorovits B
    AAPS J; 2017 Jan; 19(1):313-319. PubMed ID: 27873117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of anti-drug antibodies in preclinical pharmacokinetic assessment.
    Thway TM; Magana I; Bautista A; Jawa V; Gu W; Ma M
    AAPS J; 2013 Jul; 15(3):856-63. PubMed ID: 23653044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioanalytical considerations in the comparability assessment of biotherapeutics.
    Lee JW; Wang YM; Moxness M; DeSilva B
    Bioanalysis; 2011 Mar; 3(6):613-22. PubMed ID: 21417731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
    Coddens A; Snoeck V; Bontinck L; Buyse MA; Pine SO
    J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Anti-idiotypic Antibodies in Ligand Binding Assays for Antibody Drug Development.
    Harth S; Frisch C
    Methods Mol Biol; 2021; 2261():291-306. PubMed ID: 33420997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab.
    Mojtahed Poor S; Ulshöfer T; Gabriel LA; Henke M; Köhm M; Behrens F; Geisslinger G; Parnham MJ; Burkhardt H; Schiffmann S
    Clin Exp Immunol; 2019 May; 196(2):259-275. PubMed ID: 30656642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of a Plug-and-Play Immunogenicity Assay in Cynomolgus Monkey Serum for ADCs at Early Stages of Drug Development.
    Carrasco-Triguero M; Davis H; Zhu Y; Coleman D; Nazzal D; Vu P; Kaur S
    J Immunol Res; 2016; 2016():2618575. PubMed ID: 27092313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics.
    Wu B; Chung S; Jiang XR; McNally J; Pedras-Vasconcelos J; Pillutla R; White JT; Xu Y; Gupta S
    AAPS J; 2016 Nov; 18(6):1335-1350. PubMed ID: 27495119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
    Shankar G; Devanarayan V; Amaravadi L; Barrett YC; Bowsher R; Finco-Kent D; Fiscella M; Gorovits B; Kirschner S; Moxness M; Parish T; Quarmby V; Smith H; Smith W; Zuckerman LA; Koren E
    J Pharm Biomed Anal; 2008 Dec; 48(5):1267-81. PubMed ID: 18993008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotransformation and in vivo stability of protein biotherapeutics: impact on candidate selection and pharmacokinetic profiling.
    Hall MP
    Drug Metab Dispos; 2014 Nov; 42(11):1873-80. PubMed ID: 24947971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for the Assessment and Management of Pre-existing Drug-Reactive Antibodies During Biotherapeutic Development.
    Xue L; Clements-Egan A; Amaravadi L; Birchler M; Gorovits B; Liang M; Myler H; Purushothama S; Manning MS; Sung C
    AAPS J; 2017 Nov; 19(6):1576-1586. PubMed ID: 29110222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance.
    Song S; Yang L; Trepicchio WL; Wyant T
    J Immunol Res; 2016; 2016():3072586. PubMed ID: 27340678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space.
    Wakshull E; Quarmby V; Mahler HC; Rivers H; Jere D; Ramos M; Szczesny P; Bechtold-Peters K; Masli S; Gupta S
    AAPS J; 2017 Nov; 19(6):1656-1668. PubMed ID: 28795351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development.
    Lu Y; Khawli LA; Purushothama S; Theil FP; Partridge MA
    J Immunol Res; 2016; 2016():8141269. PubMed ID: 27642612
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics.
    Xue L; Rup B
    AAPS J; 2013 Jul; 15(3):893-6. PubMed ID: 23761225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development.
    Lee JW; Kelley M; King LE; Yang J; Salimi-Moosavi H; Tang MT; Lu JF; Kamerud J; Ahene A; Myler H; Rogers C
    AAPS J; 2011 Mar; 13(1):99-110. PubMed ID: 21240643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies.
    Johnson DE
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.